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Abstract
Noncentral nervous system cancer and the brain share an interesting and complex
relation, with an emerging body of evidence showing that cancer patients are at an
increased risk of developing cognitive problems. In contrast, population‐based studies
consistently find an inverse link between cancer and dementia, that is patients with
dementia having a lower risk of subsequently developing cancer, and cancer patients
being less often diagnosed with dementia. Different biological processes such as
inversely activated cell proliferation and survival pathways have been suggested to
have an important role underlying this inverse association. However, the effect of
methodological biases including surveillance or survival bias has not been completely
ruled out, calling into question the inverse direction of the association between cancer
and dementia. In fact, emerging evidence now suggests that cancer and dementia
might share a positive association. This narrative review summarises the current liter-
ature on cancer, cognitive problems and dementia. Moreover, different strategies will
be discussed to reduce the impact of potential methodological biases on the associa-
tion between cancer and dementia, trying to reveal the true direction of this link.
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1 | INTRODUCTION
With ageing populations worldwide, the incidence and
prevalence of age‐related diseases including cancer and
dementia are rapidly increasing. Cancer is the second leading
cause of death in the United States, and it has taken the lead
in several European countries.1,2 Early diagnosis and
improvement of treatments have ensured longer survival of
cancer patients, which in turn increases rates of long‐term
side effects, both of cancer itself and of the aggressive treat-
ments. At the same time, prevalence rates of cognitive
impairment among older individuals vary between 5% and
29%, depending on the definition used.3 In addition, over 46
million individuals worldwide are living with dementia,
which is expected to almost double every 20 years.4
A substantial body of literature suggests a link between
cancer and dementia, that is patients with dementia have a
decreased risk of subsequently being diagnosed with cancer,
and cancer patients have a lower risk of dementia.5-20 Impor-
tantly, this association is not restricted to cancer of the cen-
tral nervous system (CNS) or to long‐term adverse effects of
cancer treatments. Indeed, there is emerging evidence sug-
gesting a direct link between non‐CNS cancer and dementia.
However, the exact nature of this link as well as the mecha-
nistic underpinnings remains largely unknown.
In this narrative review, we provide a comprehensive
overview of the literature on cognitive problems in non‐
CNS cancer patients. We then focus on studies investigat-
ing the risk of cancer in patients with dementia, and the
risk of dementia in patients with cancer in the general
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population. These studies mostly show an inverse associa-
tion between these diseases. Next, an overview is given on
potential biological and methodological underpinnings of
this inverse link. Since methodological issues may affect
the direction and magnitude of this association, we subse-
quently propose several strategies that will aid in reducing
potential methodological biases in this research area.
Finally, we discuss emerging evidence that cancer and
dementia might actually share a positive association.
2 | COGNITIVE PROBLEMS IN
PATIENTS WITH NON‐CNS CANCER
The number of cancer survivors is growing due to ageing
populations, earlier detection of cancer and advances in
cancer treatments.21 This results in a large number of per-
sons confronted with long‐term side effects of cancer and
cancer treatment, such as premature menopause, congestive
heart failure and cognitive problems.
The prevalence of cognitive problems during and after
cancer treatment ranges between 17% and 75%, with a sub-
group of non‐CNS cancer survivors having long‐term cog-
nitive problems lasting up to more than 20 years after
cessation of treatment.22,23 For many years, research was
primarily directed to chemotherapy as the driving force
behind disturbances in the normal functioning of the brain
dubbed by some cancer survivors as “chemobrain.” Differ-
ent mechanisms for chemotherapy‐induced cognitive prob-
lems have been revealed and suggested, including toxicity
to neural progenitor cells, DNA damage in postmitotic neu-
rons and telomere shortening, deregulation of cytokines
and hormonal changes.24 However, studies examining the
consequences of chemotherapy on brain functioning often
were cross‐sectional and therefore provided no information
about the baseline cognitive function of cancer patients.25
More recent longitudinal studies have incorporated base-
line evaluations of cognitive functioning after surgery and
before initiation of systemic adjuvant therapy. These studies
revealed that chemotherapy may not be the only cause of
cognitive problems, as some studies found that patients
already showed lower than expected cognitive functioning
before start of chemotherapy.26-29 Moreover, imaging studies
show that prior to chemotherapy, patients may already have
altered structural and functional brain structures, including
lower white matter integrity and hyperactivation of different
brain regions, in particular the frontal and parietal lobes.30-34
Hyperactivation is often seen as a compensatory mechanism
to maintain adequate levels of task performance during inad-
equate functioning of the brain.35 For instance, a functional
magnetic resonance imaging study conducted in breast can-
cer patients prior to chemotherapy showed increased frontal
lobe activation during working memory performance,
suggesting the need for prefrontal compensation in response
to cancer.34 Changes in brain functions were not fully
explained by anxiety, depression or fatigue. However, the
time of study entry may not be appropriate, as the impact of
anaesthesia and side effects of surgery could also induce
changes in cognitive functioning. Less is known about the
cognitive functioning in cancer patients prior to surgery. Thus
far, three studies have been conducted evaluating cognitive
function in newly diagnosed breast cancer patients.36-38 Inter-
estingly, these patients also show worse neuropsychological
test performance and alterations on MRI scans compared to
controls that cannot be explained by the distress accompanied
by cancer diagnosis, suggesting that cancer itself may induce
changes in the normal functioning of the brain. Preclinical
support for this observation comes from studies showing that
immunodeficient mice engrafted with patient tumour tissue
show molecular changes in the brain similar to those seen in
neurodegeneration and brain ageing.39,40
Besides the role of cancer itself, cognitive problems in
newly diagnosed cancer patients could also be explained by
a shared pathology. For instance, genetic susceptibility,
inflammation and oxidative stress are processes related to
cancer and to cognitive decline.41,42 Furthermore, shared risk
factors such as ageing, smoking, lack of physical activity and
a poor diet could also play a role in the development of both
conditions. As yet, there are multiple candidate mechanisms
for the observed cognitive problems in cancer patients after
diagnosis and prior to subsequent treatment. More research
is needed to determine when cognitive problems in cancer
patients originates in order to distinguish the impact of can-
cer itself from the role of shared pathologies and risk factors.
3 | THE RISK OF CANCER IN
DEMENTIA PATIENTS AND THE
RISK OF DEMENTIA IN PATIENTS
WITH CANCER
Literature shows intriguing findings about the association
between cancer and cognitive problems, with multiple stud-
ies showing cancer patients at an increased risk of develop-
ing long‐term cognitive problems. Dementia is often
preceded by cognitive impairment, in which pathophysio-
logical processes underlying dementia may already be pre-
sent. Since a shared pathology between cognitive problems
and cancer has been hypothesised, a logical question
emerges whether cancer and cancer treatment are also asso-
ciated with an increased risk of dementia.
Interestingly, multiple studies suggest an inverse
association between cancer and dementia, in particular for
Alzheimer disease (AD).5-20 In 1990, Yamada et al investi-
gated risk factors for dementia in atomic‐bomb survivors
and observed that the odds of having cancer prior to AD
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was 70% lower in patients with AD compared to persons
without AD. More than a decade later, longitudinal studies
confirmed that cancer patients were at a decreased risk of
developing dementia. Moreover, these studies showed also
that patients with dementia were less likely to be diagnosed
with cancer. These findings suggest an inverse association
between cancer and dementia in both directions. This inverse
association was observed for most cancer types, including
nonmelanoma skin cancer, and was consistent across differ-
ent studies. An overview of the individual studies investigat-
ing this association is provided in Table 1.
In addition to the role of cancer itself, few retrospective
studies evaluated the effect of chemotherapy on dementia
in breast cancer survivors.43-46 All these studies used data
from the linked Surveillance, Epidemiology, and End
Results (SEER)‐Medicare database. For this reason, the
outcomes cannot be interpreted as independent. Neverthe-
less, these studies demonstrated contrasting results with
only one study showing an increased incidence of dementia
among patients treated with chemotherapy.45 Comparison
of the risk of dementia in cancer survivors after chemother-
apy with the dementia risk among cancer‐free controls
showed again an inverse association.44
Multiple biological mechanisms have been proposed sup-
porting this inverse association between cancer and dementia
in both directions. Promotion of genetic pathways involved
in cell proliferation and survival could result in an increased
cancer risk, while dementia is associated with increased cell
death. For instance, the expression of the tumour suppressor
protein p53 is often decreased in cancer, while elevated in
AD brains.47 Furthermore, the enzyme pin1 is involved in
protein folding and cell cycle regulation, and is often overex-
pressed in tumours whereas it is depleted in AD. Other can-
didate processes are opposite disturbances of the epigenome
and ultraviolet radiation exposure.17,48
Despite consistent results and suggested biological mecha-
nisms, several methodological issues driving this inverse asso-
ciation have not completely been ruled out. Therefore, careful
interpretation and critical evaluation of the observed link are
needed. Cancer and dementia are accompanied by multiple
symptoms, which can mask symptoms of other, yet undiag-
nosed diseases. Additionally, physicians could be less willing
to refer diseased patients, resulting in surveillance bias. Fur-
thermore, studying diseases in the older population may be
subject to survival bias. Since it is important to understand the
potential methodological limitations to critically review the
inverse association between cancer and dementia, the two
types of biases will be discussed in more detail.
3.1 | Surveillance bias
Surveillance bias arises when patients with a certain disease
undergo increased or decreased screening, resulting in a
respectively higher or lower probability to be diagnosed
with the studied outcome.49 For instance, patients with uri-
nary tract stones seem to have an increased risk of cancer,
whereas there is no evident biological relation between
these conditions.50 The diagnosed tumours are more often
in situ carcinomas and are smaller compared to tumours in
patients without urinary tract stones, suggesting that these
cancers are identified during the diagnostic work‐up of uri-
nary tract stones. Without the diagnostic process of the uri-
nary tract stones, patients would have been diagnosed with
cancer in a more advanced stage or not at all. Therefore,
part of the association between urinary tract stones and
cancer seems to be the result of surveillance bias.
Surveillance bias due to decreased screening could be
introduced in the investigation of the association between
cancer and dementia, since patients with these diseases
may be less likely to be screened and diagnosed with other
diseases. Several observations support this conception.
First, patients with dementia are not always able to
communicate symptoms.51 It has been observed that
dementia patients often use less pain medication for comor-
bid conditions compared to healthy controls, which may be
due to disturbances in communication or as a result of
decreased pain experience due to neurodegeneration.52,53
This is supported by the finding that cancer in dementia
patients is often diagnosed in a more advanced stage com-
pared to persons without dementia, since pain is an impor-
tant symptom of a variety of cancers.54 In turn, symptoms
of comorbid diseases in cancer patients may be attributed
to cancer by patients and their physicians, leaving the other
underlying disease unrecognised.55
Moreover, when a patient has a serious illness with a
limited life expectancy, physicians may be less prepared to
start a diagnostic work‐up for new symptoms. In the case
of dementia, patients undergo less often screening for can-
cer.56,57 It can be difficult for these patients to understand
the risks and benefits of screening.58 Additionally, the ben-
efits of cancer screening may not outweigh the harm due
to the risk of overdiagnosis and overtreatment. A study
under elderly care physicians in nursing homes showed that
end stage dementia was the primary reason to not refer
patients with suspected breast cancer.59 In cancer patients,
cognitive problems remain often unrecognised since cogni-
tive assessment is not standard practice.60 For this reason,
a diagnosis of cognitive impairment or dementia could
remain unrecognised in cancer patients.
Lastly, when a dementia patient is suspected to have
cancer, pathological confirmation through biopsies is often
omitted since it does not have therapeutic consequences.61
Several studies demonstrated that patients with dementia
and cancer often do not receive cancer treatment.54 Since
many cancer registries only register pathological confirmed
tumours, these tumours will remain unnoticed.62
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3.2 | Survival bias
Survival bias is considered as a special case of selection
bias and may occur when the studied exposure is associ-
ated with survival.63 When the exposure negatively influ-
ences survival, those exposed individuals who will survive
are likely to have some other, protective characteristics
helping them to survive. This results in a lower frequency
of the exposure among the survivors, which can be
observed as an inverse association between the exposure
and outcome.
A nice illustration is the observed association between
smoking and dementia. It has repeatedly been shown that
smoking increases the risk of dementia among younger per-
sons, while it seems to be protective for dementia in older
persons. This lower risk of dementia in older smokers is
most likely due to selection bias. Most smokers who are
susceptible for developing dementia will develop dementia
due to their smoking habits before a certain age. The group
of smokers who survive beyond this age is depleted by
those smokers who were susceptible for developing demen-
tia, resulting in a distorted low risk of dementia among
smokers in the older population. Therefore, smoking may
be falsely interpreted as protective for dementia among the
older population. Survival bias can especially affect the
results when studying the older population, since death
rates are higher among older persons, and death is often
affected by the exposure.64
Both cancer and dementia are potentially fatal diseases
and affect survival. For dementia, the median overall sur-
vival depends on the age of the patient and ranges between
6.0 years for persons aged ≤75 and 3.5 years for those
aged ≥85 years.65 Survival rates for patients with cancer
differ per cancer type and depend on the stage at diagno-
sis.1 Importantly, patients who developed both cancer and
dementia have a higher overall mortality and disease‐speci-
fic mortality compared to the patients with only one of
these conditions.66 This suggests that survival bias could
affect estimates of the association between cancer and
dementia, resulting in lower exposure rates among the dis-
eased (ie lower numbers of prevalent cancer diagnosis in
patients with dementia, and less diagnoses of dementia
before cancer development).
3.3 | Strategies to deal with surveillance and
survival bias
Few studies investigating the inverse association between
cancer and dementia have tried to overcome potential
biases. Two studies restricted the analyses to persons who
survived at least to age 80 years, trying to account for
selective mortality resulting in survival bias.6,7 The first
study by Driver et al investigated the risk of AD in 995
participants from the longitudinal community‐based Fram-
ingham Heart Study who survived at least to age 80 years.
They proposed that if the inverse effect is mainly due to
death of cancer survivors, this effect would be diminished
after exclusion of the nonsurvivors. The effect estimates
hardly changed in these sensitivity analyses (hazard ratio
(HR) among all participants = 0.81, 95% confidence inter-
val (CI) 0.59‐1.11, and among cancer survivors aged at
least 80 years = 0.81, 95% CI 0.46‐1.46)7. Bowles et al6
performed the same analysis among 2787 participants from
the prospective community‐based Adult Changes in
Thought cohort study and found a HR of 0.69, 95% CI
0.51‐0.92 among the survivors, compared to a HR of 0.73,
95% CI 0.55‐0.96 in the total study population. Related to
this approach, one study compared the effect estimates in
persons who died to the effect estimates in those who sur-
vived during follow‐up.10 They reported that the inverse
association between cancer and dementia was more pro-
nounced in the survivors (risk ratio (RR) for cancer in AD
patients in survivors 0.42, 95% CI 0.33‐0.53; in nonsur-
vivors 0.86, 95% CI 0.68‐1.06; RR for AD in cancer
patients in survivors 0.58, 95% CI 0.46‐0.72; in nonsur-
vivors 0.75, 95% CI 0.60‐0.93). These findings indicate
that the impact of survival bias on the association between
cancer and dementia is limited. However, there are some
caveats when limiting the analyses to survivors as used in
the two abovementioned methods. First, cancer and demen-
tia patients who survived may be healthier than those who
died at younger ages. Moreover, cancer patients diagnosed
with dementia, and dementia patients with cancer, have a
shorter life expectancy than those patients with only one of
these diseases. Therefore, restricting analyses to survivors
can result in selection bias and may not be the most suit-
able approach to deal with survival bias.
Few studies investigated the relation of cancer with
other diseases including stroke, automobile injuries,
osteoarthritis and macular degeneration, which were used
as negative control diseases.7-9 In case of survival bias,
cancer patients would also have a decreased risk of these
diseases. The risk of stroke, osteoarthritis and macular
degeneration after cancer was found to be increased, while
there was no relation with automobile injuries. Interest-
ingly, the risk of cancer following automobile injuries was
decreased. For this reason, the authors suggested that the
ascertainment of cancer after serious medical conditions is
limited. However, it is questionable whether these diseases
are suitable negative controls. Stroke and automobile inju-
ries are characterised by acute symptoms, making the asso-
ciation with cancer less sensitive to surveillance bias.
Moreover, there seems to be a biological mechanism under-
lying the frequently found positive relation between cancer
and stroke.67,68 Lastly, cancer shares risk factors with
osteoarthritis and macular degeneration such as obesity and
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inflammation.69,70 Therefore, the results of the association
of cancer with these negative control diseases should be
interpreted carefully.
Furthermore, several studies investigated the risk of
dementia in relation to different cancer sites or stages.5,6,8-12
Tumours originated deep in the body may progress over a
longer time until they become clinically manifest, com-
pared to tumours located at the body surface. For instance,
it would be less complicated to detect breast or skin cancer,
compared to tumours originated in the pancreas or lung.
Identifying these tumours could be easier, as well as per-
forming diagnostic work‐up such as obtaining tissue mate-
rial for pathology. Although some results suggest that the
inverse association is more pronounced for deep located
tumours, risk estimates per cancer site differ across studies.
A meta‐analysis found that the decreased risk was mostly
pronounced in head and neck, and colorectal cancer, while
the risk of prostate cancer was increased in patients with
dementia.71 Due to nonreferral of suspected cancer patients,
the risk of specific cancer types in dementia could still be
underestimated.
At last, two studies stratified follow‐up time to detect
bias. In case of bias, the decreased risk of cancer or
dementia is expected to be more pronounced in a longer
period after the diagnosis has been made. Ou et al12 found
that the risk of cancer in patients with AD within the first
year after AD diagnosis was comparable to the cancer risk
in the general population, whereas the risk was lower there-
after (standardised incidence ratio (SIR) 0.98, 95% CI 0.76‐
0.95 and 0.85, 95% CI 0.76‐0.95, respectively). In addition,
Frain et al8 determined the risk of AD during four time
periods after cancer diagnosis for different cancer types,
which was relatively constant over time depending on can-
cer type.
Despite the discussed applied strategies, potential effects
of surveillance and survival bias have not been satisfactory
ruled out. Studies with a different methodology, for exam-
ple autopsy studies, studies using genetic information, or
investigation of cancer in preclinical stages of the disease
could shed additional light on the link between cancer and
dementia.
3.4 | Autopsy studies
Searching for undiagnosed malignancies during autopsy in
patients with dementia could account for surveillance bias.
Autopsy studies show different results with respect to the
prevalence of neoplasms in patients with AD, with some
studies finding higher cancer rates in patients compared to
controls, while others finding lower a prevalence than
expected.72-74 It should be noted that autopsied dementia
patients may differ from nonautopsied dementia patients,
which could result in selection bias.75 Autopsied patients
are more likely to be Caucasian, educated beyond high
school, married and tend to have a lower Mini‐Mental State
Examination score. At present, no studies reporting on the
prevalence of AD pathology in autopsied cancer patients
have been published.
3.5 | Genetics
Evaluation of the genetic overlap between dementia and
cancer could reveal the true direction of the association
between cancer and dementia. One study used genomewide
association study summary statistics showed a positive
genetic correlation between these diseases, implying that
cancer and dementia share some genetic background.76
Shared genetic variants could modulate the risk of cancer
and dementia in the same direction, thereby pointing
towards pleiotropic effects. The strongest positive genetic
correlations were found in regions representing enhancer
marks on the genome, indicating a possible role of gene
expression regulation in the pathogenesis of both diseases.
3.6 | Preclinical stages
Identifying persons with an increased risk of developing
cancer or dementia could be another strategy to deal with
surveillance or survival bias. For instance, persons with an
increased genetic risk or a preclinical stage of the disease
could provide more insight in the association between can-
cer and dementia, since their life expectancy will be longer
compared to persons who already developed the disease.
Carcinoma in situ can be seen as a preclinical stage of can-
cer. However, not all cancer types are preceded with this
noninvasive stage and it can be hard to identify these
patients. It could be less complicated to identify patients
with an early stage of dementia.
The pathophysiological process underlying AD begins
years before the clinical diagnosis has been made.77 Mild
cognitive impairment (MCI) has the same pathological
underpinnings as AD and can be seen as a preclinical stage
of AD. Despite the fact that not every person with MCI
will eventually develop AD, over half of these persons will
progress to AD within a period of 5 years.78 In case of a
suspected tumour, it is more likely that patients with MCI
will be referred to a physician compared to AD patients.
These persons also have a longer life expectancy compared
to patients with AD. For these reasons, the relation
between cancer and AD could be explored with less influ-
ence of biases using MCI as a proxy for dementia. In a
first attempt to do so, we investigated the risk of cancer in
persons with MCI and compared this with the risk of can-
cer in dementia patients in a population‐based prospective
cohort study.20 In this study, we showed that persons with
MCI tended to have an increased risk of developing cancer
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(HR 1.24, 95% CI 0.99‐1.58), which is in contrast with the
decreased cancer risk among patients with dementia (HR
0.59, 95% CI 0.41‐0.68). Although the risk of MCI in can-
cer patients has yet to be investigated, these findings sug-
gest that the inverse association between cancer and
dementia might be based on methodological bias.
4 | EXPLORING THE CONCEPT OF
A POSITIVE ASSOCIATION
BETWEEN CANCER AND DEMENTIA
The association between cancer and dementia remains com-
plicated, since a substantial amount of bias may influence
the direction of the association. Based on the high preva-
lence of cognitive problems among cancer patients, shared
genetic traits and the increased risk of cancer in persons
with MCI, the existence of a true inverse link between can-
cer and dementia can be questioned; in fact, it is reasonable
to explore the existence of a positive association which
may be more plausible from a mechanistic point of view.
Support for a positive association between cancer and
dementia is found in the notion that various processes are
involved in the pathogenesis of cancer and dementia, such
as inflammation, oxidative stress and angiogenesis.
Increased inflammatory biomarkers such as fibrinogen and
interleukin‐6 are associated with lower cognitive perfor-
mance and cognitive decline. Different proteins are
involved in this process, including the amyloid beta (Aβ)
peptide. Aβ is the product of amyloid precursor protein
(APP) proteolysis and can be measured in blood, cere-
brospinal fluid and by imaging. Accumulation of plaques
containing Aβ is one of the hallmark features of AD and is
currently the earliest detectable pathological change in the
preclinical stage of AD.77 It has been suggested that Aβ is
also involved in cancer, since APP is overexpressed in sev-
eral tumours and is associated with cell proliferation,
migration and invasion.79 Moreover, the BRCA1 protein,
an important tumour suppressor protein, has recently been
linked to AD. Overactivation of BRCA1 can indirectly
result in Aβ pathology and can promote neuronal cell
death.80 Furthermore, plasma levels of Aβ‐40 and Aβ‐42
are increased in patients with different cancer types.81
DNA damage caused by oxidative stress and deficient
DNA repair mechanisms are also important in the patho-
genesis of cancer and dementia. Genetic polymorphisms
associated with a decreased capacity to repair damaged
DNA can be related to an increased risk of cancer and cog-
nitive impairment. Furthermore, syndromes such as xero-
derma pigmentosum and ataxia telangiectasia are caused by
genetic defects in DNA damage repair mechanisms and are
characterised by an increased risk of cancer and cognitive
problems, indicating a shared pathology.24
5 | CONCLUSION
The relation between non‐CNS cancer and the brain is com-
plex. Whereas an emerging body of research has shown that
cancer patients often experience cognitive problems, the risk
of developing dementia in cancer survivors is still unclear.
Methodological issues such as surveillance and survival bias
complicate the investigation of the association between can-
cer and dementia in both directions. Although multiple
attempts have been made to deal with these biases, this is
still insufficiently taken care of, and consensus is lacking
about the driving force behind the inverse association.
Understanding the contrasting but also the overlapping
mechanisms underlying cancer and dementia can provide
insight into prevention and therapeutic strategies for both
diseases. Therefore, it is necessary to reveal the true nature
of the association, for instance by focussing more on the
preclinical stages of cancer and dementia.
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